Pharmacologic anticoagulation reversal in the emergency department

Advanced Emergency Nursing Journal

Volumn 33, Issue 3, 2011, Pages 212-223

  Lemon Jr , Stephen J ^a   Crannage, Andrew J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

anticoagulation; antidote; hemostasis; reversal

Indexed keywords

ANTICOAGULANT AGENT; HEMOSTATIC AGENT;

BLEEDING; CHEMICALLY INDUCED DISORDER; EMERGENCY NURSING; HUMAN; METHODOLOGY; NURSING; NURSING EDUCATION; REVIEW;

ANTICOAGULANTS; EDUCATION, NURSING, CONTINUING; EMERGENCY NURSING; HEMORRHAGE; HEMOSTATICS; HUMANS;

EID: 80052212754     PISSN: 19314485     EISSN: None     Source Type: Journal    
DOI: 10.1097/TME.0b013e31822638ae     Document Type: Review

References (42)

1. Aguilar, M. I., Hart, R. G., Kase, C. S., Freeman, W. D., Hoeben, B. J., Garcia, R. C.,.., Yasaka, M. (2007). Treatment of warfarin-associated intrac-erebral hemorrhage: Literature review and expert opinion. Mayo Clinic Proceedings, 82(1), 82-92. doi: 10.4065/82.1.82. (Pubitemid 46036324)
2. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008). Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest, 133(Suppl), 160s-198s. doi 10.1378/chest.08-0670. (Pubitemid 351892967)
3. Bang, C. J., Berstad, A., & Talstad, I. (1991). Incomplete reversal of enoxaparin-induced bleeding by pro-tamine sulfate. Haemostasis, 21(3), 155-160. doi: 10.1159/000216220.
4. Beshay, J. E., Morgan, H., Madden, C., Yu, W., & Sarode, R. (2010). Emergency reversal of anticoagula-tion and antiplatelet therapies in neurosurgical patients. Journal of Neurosurgery, 112(2), 307-318. doi: 10.3171/2009.7.JNS0982.
5. Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J., Levi, M. (2002). Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pen-tasaccharide fondaparinux in healthy volunteers. Circulation, 106(20), 2550-2554. doi: 10.1161/01.CIR. 0000038501.87442.02. (Pubitemid 35340690)
6. Butler, K. D., Dolan, S. L., Talbot, M. D., & Wal-lis, R. B. (1993). Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coagulation & Fibrinolysis, 4(3), 459-464. doi: 10.1097/00001721-199306000-00011. (Pubitemid 23166543)
7. Crowther, M. A., Julian, J., McCarty, D., Douketis, J., Kovacs, M., Biagoni, L.,.., Ginsberg, J. (2000). Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial. Lancet, 356(9241), 1551-1553. doi: 10.1016/S0140-6736(00)03125-1.
8. Crowther, M. A., & Warkentin, T. E. (2008). Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood, 111(10), 4871-4879. doi: 10.1182/blood-2007-10-120543.
9. Desmurs-Clavel, H., Huchon, C., Chatard, B., Negrier, C., & Dargaud, Y. (2009). Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thrombosis Research, 123(5), 796-798. doi: 10.1016/j.thromres.2008.07.007.
10. Hanley, J. P. (2004). Warfarin reversal. Journal of Clinical Pathology, 57(11), 1132-1139. doi:10.1136/jcp.2003.008904. (Pubitemid 39486516)
11. Hirsh, J., & Levine, M. N. (1992). Low molecular weight heparin. Blood, 79(1), 1-17. Retrieved from http://bloodjournal.hematologylibrary.org/
12. Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008). Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest, 133(Suppl), 141s-159s. doi: 10.1378/chest.08-0689. (Pubitemid 351892966)
13. Hoffman, M. (2003). Laboratory monitoring of high-dose factor VIIa therapy. Annals of Internal Medicine, 139(9), 791. Retrieved from http://www.annals.org/ (Pubitemid 38129081)
14. Irani, M. S., White, H. J., Jr., & Sexon, R. G. (1995). Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. The American Journal of Cardiology, 75(5), 422-423. doi: 10.1016/S0002-9149(99) 80572-4.
15. Kessler, C. M. (2004). Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complications. Seminars in Hematology, 41(1 Suppl 1), 44-50. doi: 10.1053/j.seminhematol.2003. 11.010. (Pubitemid 38182716)
16. Key, N. S., & Nelsestuen, G. L. (2004). Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Seminars in Hematology, 41(1 Suppl 1), 51-54. doi: 10.1053.j.seminhematol.2003.11.011. (Pubitemid 38182717)
17. Lankiewics, M. W., Hays, J., Friedman, K. D., Tinkoff, G., & Blatt, P. M. (2006). Urgent reversal of warfarin with prothrombin complex concentrate. Journal of Thrombosis and Haemostasis, 4(5), 967-970. doi: 10.1111/j.1538-7836. 2006.01815.x.
18. Lethagen, S. (1997). Desmopressin-a haemostatic drug: state-of-the-art review. European Journal of Anaesthesiology Supplement, 14, 1-9. doi: 10.1097/00003643-199703001-00002.
19. Levi, M. (2009). Emergency reversal of antithrombotic therapy. Internal and Emergency Medicine, 4(2), 137-145. doi: 10.1007/s11739-008-0201-8.
20. Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010). Safety of recombinant activated factor VII in randomized clinical trials. The New England Journal of Medicine, 363(19), 1791-1800. doi: 10.1056/NEJMoa1006221.
21. Makris, M. (2003). Management of excessive anticoagu-lation or bleeding. Seminars in Vascular Medicine, 3(3), 279-284. doi: 10.1055/s-2003-44464. (Pubitemid 37280717)
22. Malherbe, S., Tsui, B. C., Stobart, K., & Koller, J. (2004). Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recom-binant activated factor VII. Anesthesiology, 100(2), 443-445. doi: 10.1097/00000542-200402000-00038. (Pubitemid 38133716)
23. McNeill, S. A., Ewing, J. C., Wallace, W. A., & Stewart, L. H. (1998). Venous infarction of a testicle following factor IX concentrate (DEFIX). British Journal of Haematology, 101(1), 210. doi: 10.1046/j.1365-2141.1998. 0703c.x. (Pubitemid 28197799)
24. Oh, J. J., Akers, W. S., Lewis, D., Ramaiah, C., & Flynn, J. D. (2006). Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy, 26(4), 569-577. doi: 10.1592/phco.26.4.576.
25. Package Insert. (2002). Aquamephyton (phytonadione injection). West Point, PA: Merck and Co., Inc.
26. Package Insert. (2004). Profilnine SD (factor IX complex). Los Angeles, CA: Grifols Biologicals, Inc. Retrieved May 5, 2011, from http://www.grifolsusa. com/profilnine.html
27. Package Insert. (2006). Bebulin VH (factor IX complex). Westlake Village, CA: Baxter HealthCare Corporation. Retrieved May 10, 2011, from http://www.abopharmaceuticals.com/
28. Package Insert. (2007). Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb Company.
29. Package Insert. (2007). DDAVP (desmopressin). Bridge-water, NJ: Sanofi-Aventis U.S., LLC.
30. Package Insert. (2008). Protamine sulfate. Schaumburg, IL: APP Pharmaceuticals, LLC.
31. Package Insert. (2010). NovoSeven RT (coagulation factor VIIa [recombinant]). Princeton, NJ: Novo Nordisk Pharmaceuticals.
32. Pindur, G., & Morsdorf, S. (1999). The use of pro-thrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thrombosis Research, 95(4 Suppl 1), S57-61. doi: 10.1016/S0049-3838(99)00085-7. (Pubitemid 29461049)
33. Preston, F. E., Laidlaw, S. T., Sampson, B., & Kitchen, S. (2002). Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. British Journal of Haematology, 116(3), 619-624. doi: 10.1046/j.0007-1048.2001.03295.x. (Pubitemid 34178663)
34. Reiter, R. A., Mayr, F., Blazicek, H., Galehr, E., Jilma-Stohlawetz, P., Domanovits, H., & Jilma, B. (2003). Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood, 102(13), 4594-4599. doi: 10.1182/blood-2002-11-3566. (Pubitemid 37494129)
35. Roberts, H. R., Monroe, D. M., & White, G. C. (2004). The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood, 104(13), 3858-3864. doi: 10.1182/blood-2004-06-2223. (Pubitemid 39620130)
36. Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008). Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest, 133(Suppl), 257s-298s. doi: 10.1378/chest.08-0674. (Pubitemid 351892969)
37. Van Ryn-McKenna, J., Cai, L., Ofosu, F. A., Hirsh, J., & Buchanan, M. R. (1990). Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thrombosis and Haemostasis, 63(2), 271-274. (Pubitemid 20128194)
38. Veshchev, I., Elran, H., & Salame, K. (2002). Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin-related coagulopathy in patients with acute subdural hematoma. Medical Science Monitor, 8(12), CS98-CS100. (Pubitemid 36119188)
39. Warkentin, T. E., & Crowther, M. A. (2002). Reversing anticoagulants both old and new. Canadian Journal of Anaesthesia, 49(6), S11-S25.
40. Watson, R. A., Ansbacher, R., Barry, M., Deshon, G. E., & Agee, R. E. (1983). Allergic reaction to protamine: A late complication of elective vasectomy. Urology, 22(5),493-495. doi: 10.1016/0090-4295(83)90226-1. (Pubitemid 14201728)
41. Weitz, J. I. (2011). Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. In Brunton, B. A. Chabner, & B. C Knollmann.Goodman & Gilman's the pharmacological basis of therapeutics, (12th ed., Chap. 30). Retrieved from http://www.accesspharmacy.com/content.aspx?aID=16668944.
42. Zieve, P. D., & Solomon, H. M. (1969). Variations in the response of human beings to vitamin K1. The Journal of Laboratory and Clinical Medicine, 73(1), 103-110.